Repros Therapeutics Inc. (RPRX) Announces the Offering of Unregistered Shares of Common Stock in the Amount of $23.6 Million  
9/5/2012 9:44:01 AM

THE WOODLANDS, Texas, Sept. 4, 2012 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) announced today that it entered into a purchase agreement with several institutional investors to sell an aggregate of 2,145,636 shares of common stock at $11 per share, in a private placement for gross proceeds of approximately $23.6 million, before deducting offering expenses. The proceeds will be used to fund the Company's Androxal® and Proellex® programs. Closing is expected to occur later this week.